Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 21 January 2026 - 27 January 2026

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead Sciences shares rose 1.8% to $140.24 Tuesday afternoon, hitting a 12-month high of $141.69 earlier in the session. Citi, Truist, and BMO raised price targets following upbeat analyst notes and strong momentum for the company’s HIV prevention drug Yeztugo. Investors await early February results and Gilead’s earnings, expected around Feb. 10.
27 January 2026
·····
AbbVie stock rises as insurers crater and the Fed week kicks off

AbbVie stock rises as insurers crater and the Fed week kicks off

AbbVie shares rose 1.5% to $224.12 Tuesday, peaking at $226.83 as drugmakers outperformed health insurers. UnitedHealth plunged 20%, Humana fell 19%, and CVS dropped 14% after a proposed 0.09% Medicare Advantage rate hike. The S&P 500 hit a new high ahead of the Fed’s meeting. Investors await AbbVie’s Feb. 4 earnings for 2026 guidance.
27 January 2026
·····
AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie shares rose 0.4% to $220.10 Monday, moving between $217.15 and $221.48 as investors awaited its Feb. 4 earnings report. Health-care stocks held firm, with the sector ETF up 0.4% and Johnson & Johnson and Pfizer also gaining. AbbVie’s upcoming results will highlight its immunology drugs as it faces pressure from declining Humira sales and recent policy deals. Traders are watching Wednesday’s Fed decision before the earnings release.
26 January 2026
·····
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

New York, Jan 23, 2026, 19:39 EST — After-hours Gilead Sciences shares climbed 3.65%, closing at $135.93 on Friday. The stock gained momentum after fresh breast cancer data refocused attention on the company’s oncology efforts. (Yahoo Finance) Gilead announced that full Phase 3 data from the ASCENT-04/KEYNOTE-D19 trial have been published in the New England Journal of Medicine. The study showed Trodelvy combined with Keytruda outperformed Keytruda plus chemotherapy for progression-free survival, which tracks how long patients live before cancer advances. The combo cut the risk of disease progression or death by 35%, with median progression-free survival reaching 11.2 months
24 January 2026
····
Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

New York, January 22, 2026, 17:37 EST — Trading after the bell. Eli Lilly and Company shares gained roughly 0.8% in after-hours Thursday, last seen at $1,087.38, up $8.81. During the session, the stock fluctuated between $1,072.46 and $1,095.15. Investors are once again focusing on a key concern for Lilly: the duration patients remain on its blockbuster weight-loss drugs and the outcomes after discontinuation. Lilly’s obesity segment drives its growth story, so even minor changes in patient persistence expectations can send revenue forecasts—and its lofty stock valuation—reeling. A Reuters report on Thursday spotlighted real-world data from analytics firm nference showing
23 January 2026
····
Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

New York, Jan 22, 2026, 17:46 EST — After-hours Johnson & Johnson shares ended Thursday roughly 0.3% higher at $218.49, after moving between $217 and $221.86 during the session. Trading volume hit around 13 million shares. The move was modest, but the backdrop is anything but. J&J’s initial glimpse at 2026 arrives amid mounting U.S. pressure on drug pricing and tariffs, with investors still eyeing the ongoing talc litigation closely. On Wednesday, the company projected 2026 sales between $99.5 billion and $100.5 billion, with adjusted earnings of $11.43 to $11.63 per share—beating analyst expectations despite a drag from a Trump-era
22 January 2026
·····
Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

New York, January 21, 2026, 17:55 EST — After-hours Johnson & Johnson shares dipped 0.05% to $218.01 in after-hours trading Wednesday, swinging from a low of $209.20 to a high of $218.61. Investors balanced the company’s 2026 forecast with fresh scrutiny over talc-related lawsuits. The numbers are crucial as J&J aims to prove it can sustain growth despite mounting challenges. Stelara, one of its top drugs, is up against tougher competition and growing U.S. scrutiny over drug pricing. Tariffs on medical devices add another layer of cost pressure. After a strong 2025, the stock entered the earnings report riding high,
22 January 2026
·····
Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

New York, January 21, 2026, 17:20 EST — After-hours Eli Lilly’s stock jumped 3.6% on Wednesday, finishing at $1,078.52. The boost came after the company announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy designation to its experimental ovarian cancer drug. (Stock Titan) The Breakthrough Therapy program aims to fast-track the development and review of drugs for serious diseases when early data points to a significant improvement over current options. For investors, this can be crucial—it might speed up regulatory timelines, though it doesn’t guarantee approval. (U.S. Food and Drug Administration) Lilly revealed it will release its fourth-quarter
21 January 2026
·····
RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus

RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus

New York, Jan 21, 2026, 12:09 EST — Regular session. RAPT Therapeutics (RAPT.O) held steady on Wednesday, trading around $57.60 midday on Nasdaq. The shares ticked up just 0.05% during the session. After Tuesday’s sharp reprice, the shares are trading more like a deal spread than a high-flying biotech stock. That matters because what’s next largely boils down to routine moves: filings, kicking off a tender offer, and then waiting on regulators. That process could push the gap to the bid either wider or tighter. GSK is set to buy the California biotech at $58 a share in cash, valuing
21 January 2026
·····
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

New York, Jan 20, 2026, 20:41 EST — Market closed. Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up. (Finviz) The update is crucial as Merck aims to expand its growth story beyond Keytruda, its best-selling cancer drug, ahead of competition and cheaper alternatives hitting the market later this decade. The company recently told investors it expects new growth drivers to generate up to $70 billion in revenue by the mid-2030s. (Reuters) Merck managed
21 January 2026
·······
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

NEW YORK, Jan 20, 2026, 18:51 EST — After-hours Rapt Therapeutics (NASDAQ: RAPT) surged roughly 64% to $57.57 in after-hours trading Tuesday following news that Britain’s GSK will acquire the U.S. biotech. GSK’s $58-a-share cash bid values the deal at about a 65% premium over Monday’s close. This is the first big move by CEO Luke Miels, who just took charge a few weeks ago. Jefferies analyst Michael Leuchten noted that the food allergy sector “is not a crowded market right now,” as GSK braces for patent losses on its HIV drug dolutegravir. Shares in GSK slipped 1.6% in London
21 January 2026
·····
1 2 3 4 … 12

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop